Ossium’ strategy to develop advanced stem cell therapies is driven by extensive access to donor bone marrow. According to Ossium, the company has secured exclusive access to 47% of the bone marrow from deceased donors in the U.S., with a path to reach 85% by 2026.
Ossium has used its donor bank to address constraints of stem cell therapies across all stages of the supply chain. The company’s IP covers high-quality cell recovery from deceased donors, cryogenic preservation, high-yield thaw, and ultimately, directed use across multiple diseases.